Cubist Systematic Strategies LLC purchased a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 592,250 shares of the company's stock, valued at approximately $12,360,000. Cubist Systematic Strategies LLC owned about 0.09% of Genmab A/S at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of GMAB. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S in the 4th quarter worth about $33,804,000. Marshall Wace LLP lifted its position in shares of Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock valued at $23,422,000 after buying an additional 694,243 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Genmab A/S by 18,959.1% during the 4th quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after acquiring an additional 508,104 shares during the period. JPMorgan Chase & Co. increased its holdings in Genmab A/S by 3,049.3% in the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after acquiring an additional 394,670 shares during the last quarter. Finally, Trexquant Investment LP raised its stake in Genmab A/S by 495.1% in the 4th quarter. Trexquant Investment LP now owns 379,936 shares of the company's stock valued at $7,929,000 after acquiring an additional 316,089 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Trading Up 2.6%
Shares of NASDAQ GMAB traded up $0.50 during midday trading on Monday, hitting $19.86. 1,517,884 shares of the company's stock were exchanged, compared to its average volume of 1,091,777. The business's fifty day moving average price is $20.07 and its two-hundred day moving average price is $20.86. The company has a market cap of $12.73 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 2.65 and a beta of 1.04. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.41.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.05. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on GMAB shares. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Truist Financial cut their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and an average target price of $39.17.
Get Our Latest Research Report on GMAB
Genmab A/S Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
